NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
SN BioScience
AbbVie
Incyte Corporation
TransThera Sciences (Nanjing), Inc.
Cyteir Therapeutics, Inc.
BeiGene
Sellas Life Sciences Group
Vincerx Pharma, Inc.
AstraZeneca
Mundipharma Research Limited
Rhizen Pharmaceuticals SA
Xencor, Inc.
TransThera Sciences (Nanjing), Inc.
Exelixis
HiberCell, Inc.
MacroGenics
Stanford University
Syros Pharmaceuticals
AstraZeneca
Eastern Cooperative Oncology Group
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
Hoffmann-La Roche
AbbVie
AbbVie
Bayer
Incyte Corporation
Gilead Sciences
Eli Lilly and Company
Institut Bergonié
Incyte Corporation
AstraZeneca
Abramson Cancer Center at Penn Medicine
Celgene
PharmaMar
University of Wisconsin, Madison
AbbVie
SWOG Cancer Research Network
Oncology Institute of Southern Switzerland
Swiss Cancer Institute
Pfizer
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Beth Israel Deaconess Medical Center
Alliance for Clinical Trials in Oncology
Cancer Trials Ireland
Northwestern University